PRTA: Prothena Corporation plc Company Profile & Statistics

About

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.

Info & Links

CEO

Gene G. Kinney

Headquarters

77 SIR JOHN ROGERSON'S QUAY, BLOCK C, GRAND CANAL DOCKLANDS
DUBLIN, L2 D02 VK60, IRELAND

Auditor

KPMG LLP

Share holders

5,221

Employees

173

Prothena Corporation plc Statistics

Valuation Measures

Market Capitalization²

648.95M

Enterprise Value

129.69M

Enterprise Value/EBITDA(ttm)

-0.80

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

5.16

Price to Book(mrq)

1.29

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-98.86%

Profit Margin(ttm)

-42965.68%

Return on Equity(ttm)

-24.19%

Return on Invested Capital(ttm)

-25.95%

Return on Assets(ttm)

-20.59%

Income Statement

Revenue(ttm)

133.35M

Revenue Per Share(ttm)

2.48

Gross Profit(ttm)

133.35M

EBITDA(ttm)³

-162.97M

Net Income Available to Common(ttm)

-131.83M

Diluted EPS(ttm)

-2.48

Share Statistics

Beta (5Y Monthly)

0.09

52-Week Change

-65.81%

S&P 500 52-Week Change

25.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

53.81M

Dividend Yield

0.00%

Float⁴

38.69M

% Held by Insiders

28.10%

% Held by Institutions

97.08%

Balance Sheet

Total Cash(mrq)

519.26M

Total Cash Per Share(mrq)

9.65

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

11.52%

Quick Ratio(mrq)

11.52%

Book Value Per Share(mrq)

9.93

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.90

Free Cash Flow(ytd)

-102.53M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

PRTA

Prothena Corporation plc

Prothena Corporation plc Profile